Use of comprehensive genomic profiling to direct point-of-care management of patients with gynecologic cancers.

ABSTRACT:

Objective

To determine the feasibility and clinical utility of using comprehensive genomic profiling (CGP) in the course of clinical care to identify clinically relevant tumor genomic alterations for patients with either rare or refractory gynecologic cancers to facilitate point-of-care management. Use of an expert, multidisciplinary, institutional molecular tumor board (MTB) assessment is discussed regarding input on putative targeted options for individualized therapy.

Methods

A prospective clinical trial is ongoing. We report on the initial 69 patients with gynecologic cancers that were either rare or refractory to standard therapy. CGP was performed by Foundation Medicine, Inc. Genomic alterations were reviewed by members of an MTB. Consensus recommendations on genomical

SUBMITTER: Rodriguez-Rodriguez L 

PROVIDER: S-EPMC5796528 | biostudies-literature | 2016 Apr

REPOSITORIES: biostudies-literature